Cofactor Genomics Validates New NSCLC Biomarker Test

A new clinical study shows the OncoPrism-NSCLC test successfully identifies patient responses to immunotherapy.

Updated on Oct. 16, 2026 in Cancer

Isometric editorial illustration of a glass medical centrifuge vial on a flat, clean surface, representing genomic diagnostic testing. — Cofactor Genomics released a clinical validation study confirming its OncoPrism-NSCLC biomarker test accurately predicts patient response to immune checkpoint inhibitor therapy. AI Illustration. Upload story photo >

Live Poll

Do you believe advanced genetic diagnostic testing is necessary to improve cancer treatment outcomes?

Cofactor Genomics has published a clinical validation study for its OncoPrism-NSCLC biomarker test, confirming its efficacy in identifying immune checkpoint inhibitor responses. The research, based on data from 17 U.S. health care systems, also highlights the biomarker's presence in five other cancer types.

Why it matters

The study aims to improve precision oncology for lung cancer patients eligible for immune checkpoint inhibitor therapy. By providing better predictive data, the test could help clinicians optimize treatment plans when used alongside standard PD-L1 testing.

The clinical validation utilized data from 17 U.S. health care systems to confirm the biomarker's utility. Patients with high test scores demonstrated a doubled median overall survival compared to those who did not.

The players

Cofactor Genomics

This St. Louis-based biotechnology company specializes in predictive diagnostics and clinical genomics to advance precision medicine.

npj Precision Oncology

This peer-reviewed journal publishes high-impact research regarding the implementation of precision medicine in clinical practice.

The details

Researchers calibrated the test for non-small cell lung cancer by integrating RNA signals from the tumor-immune microenvironment. The study indicates that the biomarker is also present in cancers such as clear cell renal cell carcinoma and triple-negative breast cancer.

October 16, 2026: Cofactor Genomics published the OncoPrism-NSCLC clinical validation study.

The Big Picture

This study draws on data from the PREDAPT clinical trial to establish the test's efficacy across a broad range of U.S. health care settings.

The study suggests that clinicians may soon use OncoPrism alongside standard PD-L1 testing to better tailor lung cancer treatment. Patients may benefit from more personalized immunotherapy plans that improve survival outcomes.

The takeaway

This test offers a more precise method for predicting how patients might respond to immune checkpoint inhibitor therapies. It highlights the potential for using RNA-based biomarkers to supplement current standard-of-care diagnostic tests.